- Home
- MAX vs BCYC Comparison
MAX vs BCYC Comparison
Compare MAX & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- BCYC
- Stock Information
- Founded
- MAX 2014
- BCYC 2009
- Country
- MAX United States
- BCYC United Kingdom
- Employees
- MAX N/A
- BCYC N/A
- Industry
- MAX Industrial Machinery/Components
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- MAX Industrials
- BCYC Health Care
- Exchange
- MAX Nasdaq
- BCYC Nasdaq
- Market Cap
- MAX 582.4M
- BCYC 566.5M
- IPO Year
- MAX 2020
- BCYC 2019
- Fundamental
- Price
- MAX $10.35
- BCYC $8.05
- Analyst Decision
- MAX Strong Buy
- BCYC Buy
- Analyst Count
- MAX 6
- BCYC 10
- Target Price
- MAX $17.92
- BCYC $25.00
- AVG Volume (30 Days)
- MAX 419.3K
- BCYC 304.0K
- Earning Date
- MAX 07-30-2025
- BCYC 08-05-2025
- Dividend Yield
- MAX N/A
- BCYC N/A
- EPS Growth
- MAX N/A
- BCYC N/A
- EPS
- MAX 0.28
- BCYC N/A
- Revenue
- MAX $1,002,364,000.00
- BCYC $25,722,000.00
- Revenue This Year
- MAX $24.09
- BCYC $7.35
- Revenue Next Year
- MAX $11.18
- BCYC N/A
- P/E Ratio
- MAX $37.31
- BCYC N/A
- Revenue Growth
- MAX 148.62
- BCYC N/A
- 52 Week Low
- MAX $7.33
- BCYC $6.10
- 52 Week High
- MAX $20.91
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- MAX 45.90
- BCYC 55.72
- Support Level
- MAX $10.05
- BCYC $7.06
- Resistance Level
- MAX $11.14
- BCYC $8.12
- Average True Range (ATR)
- MAX 0.37
- BCYC 0.40
- MACD
- MAX -0.07
- BCYC 0.12
- Stochastic Oscillator
- MAX 26.43
- BCYC 95.20
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.